Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia

Abstract

Background

Heterozygous loss-of-function mutations in the progranulin (PGRN) gene (GRN) cause a reduction in PGRN and lead to the development of frontotemporal dementia (FTD-GRN). PGRN is a secreted lysosomal chaperone, immune regulator, and neuronal survival factor that is shuttled to the lysosome through multiple receptors, including sortilin. Here, we report the characterization of latozinemab, a human monoclonal antibody that decreases the levels of sortilin, which is expressed on myeloid and neuronal cells and shuttles PGRN to the lysosome for degradation, and blocks its interaction with PGRN.

Methods

In vitro characterization studies were first performed to assess the mechanism of action of latozinemab. After the in vitro studies, a series of in vivo studies were performed to assess the efficacy of a mouse-cross reactive anti-sortilin antibody and the pharmacokinetics, pharmacodynamics, and safety of latozinemab in nonhuman primates and humans.

Results

In a mouse model of FTD-GRN, the rodent cross-reactive anti-sortilin antibody, S15JG, decreased total sortilin levels in white blood cell (WBC) lysates, restored PGRN to normal levels in plasma, and rescued a behavioral deficit. In cynomolgus monkeys, latozinemab decreased sortilin levels in WBCs and concomitantly increased plasma and cerebrospinal fluid (CSF) PGRN by 2- to threefold. Finally, in a first-in-human phase 1 clinical trial, a single infusion of latozinemab caused a reduction in WBC sortilin, tripled plasma PGRN and doubled CSF PGRN in healthy volunteers, and restored PGRN to physiological levels in asymptomatic GRN mutation carriers.

Conclusions

These findings support the development of latozinemab for the treatment of FTD-GRN and other neurodegenerative diseases where elevation of PGRN may be beneficial.

Trial registration ClinicalTrials.gov, NCT03636204. Registered on 17 August 2018, https://clinicaltrials.gov/ct2/show/NCT03636204.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12967-023-04251-y.

Background

Frontotemporal dementia (FTD) is a rare, early-onset form of dementia with an estimated prevalence of 4 to 22 per 100000 people aged younger than 64 years [1–3]. FTD is composed of several clinical phenotypes that manifest as changes in behavior, personality, language, cognitive skills, and motor function, and FTD is associated with synapse loss, gliosis, neuronal loss, and, ultimately, gross atrophy in the frontal and temporal lobes of the brain [2, 4–6]. The disease progresses rapidly and is associated with an estimated life expectancy of 7–9 years after symptom onset [7].

A family history of FTD is present in 20–40% of cases, and 10% of cases are inherited in an autosomal dominant pattern [8–11]. Most of the genetic component is accounted for by a mutation in 1 of 3 genes: progranulin (GRN), microtubule-associated protein tau, and chromosome 9 open reading frame 72 (C9orf72) [7]. GRN mutations have been identified in approximately 10–23% of people with a family history consistent with autosomal dominant FTD and in approximately 3% of patients with FTD of apparently sporadic origin [12]. More than 100 GRN-heterozygous loss-of-function (LOF) mutations have been identified [7, 13]. GRN mutations cause disease with a wide range of ages of onset and phenotypic variability, even within families [7, 13]. Though the clinical presentation and age of onset are impacted by additional genetic modifiers such as TMEM106B [14–17], the disease penetrance approximates 100%, making GRN mutations causal for FTD [18–20].

Because progression to dementia is practically certain in GRN mutation carriers, it is imperative to develop effective treatments for FTD. Progranulin (PGRN) levels are 50% to 70% below normal in the plasma and CSF of both affected patients and asymptomatic GRN mutation carriers (aFTD-GRN) [21–23]. Thus, restoring PGRN levels to a normal range may be an effective therapeutic approach for FTD caused by GRN LOF mutations (FTD-GRN).

Identified receptors for PGRN include sortilin [24, 25], ephrin type-A receptor 2 [26], notch [27], epidermal growth factor receptor [28], and mannose 6-phosphate receptor (M6PR) and low-density lipoprotein receptor–related protein 1 (LRP1), both of which bind PGRN in conjunction with the secreted protein prosaposin [29]. Sortilin binds extracellular PGRN and targets it for lysosomal degradation [25]. Polymorphic variants of the sortilin gene (SORT1) have been linked to PGRN levels in serum, as well as to FTD susceptibility [24, 30, 31]. Further, genetic ablation of Sort1 in mice led to 2- to threefold higher levels of PGRN, and knockdown of SORT1 in cultured HeLa cells has been shown to increase extracellular PGRN [24, 25]. We therefore hypothesized that a molecule that blocks the sortilin-PGRN interaction and/or decreases sortilin levels would mimic the genetic ablation of Sort1. Accordingly, these actions would be expected to increase the levels of residual PGRN in GRN mutation carriers, restore PGRN back to physiological levels, and slow or halt the progression of FTD-GRN [32].

Latozinemab (AL001) is a recombinant monoclonal antibody that binds specifically to sortilin, prevents sortilin-PGRN interactions, and facilitates a decrease in the levels of sortilin. Latozinemab increases the levels of PGRN in plasma and cerebrospinal fluid (CSF) and has the potential to slow disease progression in carriers of heterozygous LOF GRN mutations [32, 33], as well as in other neurodegenerative diseases where genetic mutations reduce PGRN levels, such as Parkinson’s disease [34, 35], Alzheimer’s disease [36], amyotrophic lateral sclerosis [37, 38], and limbic-predominant age-related TDP-43 encephalopathy [39].

Here, we report a comprehensive assessment from initial drug discovery to a first-in-human study, detailing the pharmacology, pharmacokinetics (PK), and pharmacodynamics (PD) of latozinemab. We first characterized the mechanism of action of latozinemab in vitro and then demonstrated target engagement of S15JG, a murine cross-reactive anti-sortilin antibody, and latozinemab in vivo in mouse and nonhuman primate studies, respectively. These preclinical studies led to a first-in-human phase 1 clinical trial designed to evaluate the safety, tolerability, PK, and PD of a single infusion of latozinemab in healthy volunteers (HVs) and aFTD-GRN participants.

Methods

Antibody generation

Latozinemab (AL001) is a human monoclonal immunoglobulin (IgG) G1m17,1 kappa antibody generated against human receptor sortilin and derived from human germlines IGHV4-B and IGKV2-28. Latozinemab was generated and affinity-matured through collaboration between Alector and Adimab (Lebanon, New Hampshire, USA) to optimize in vitro and in vivo activity and to ensure manufacturing development capability [40]. Three point mutations, L234 to A234, L235 to A235, and P331 to S331 (Kabat numbering system; L239L240 and P336 in sequential numbering), were made to the heavy chain to minimize effector functions, such as Fc gamma receptor binding, complement activation, and antibody-dependent cell-mediated cytotoxicity (ADCC) [41–43]. Reduction of Fc gamma receptor binding, complement activation, and ADCC have been verified by Alector. Minimization of the effector functions is a desired characteristic for latozinemab, which is intended for chronic administration to study participants and patients.

In vitro cell-based assays of latozinemab

Anti-sortilin antibody binding to human sortilin in HEK293T cells. A stable HEK293T cell line expressing human sortilin was established by viral infection of a proprietary plasmid expressing human sortilin (GenScript Biotech, Piscataway, NJ). Cells were selected using hygromycin resistance, and a high-expressing monoclonal cell line was established. Parental HEK293T cells were utilized for control. For the binding assay, HEK293T cells were harvested by trypsinization, washed in PBS, and then counted and plated on 96-well plates at 1 × 10⁵ cells/well. The plates were spun at 1400 rpm for 3 min, and latozinemab or control antibodies were added in fluorescence-activated cell sorting (FACS) buffer (PBS + 2% fetal bovine serum [FBS]) and incubated on ice for 1 h. Cells were subsequently centrifuged as before and washed thrice with FACS buffer. Cells were then incubated with goat anti-human phycoerythrin (PE)–conjugated secondary antibody (1:100; Southern Biotech, Birmingham, AL; cat. #2040–09, lot #C1316-Q487) in FACS buffer for 30 min on ice. Cells were again washed thrice with FACS buffer and analyzed on an Intellicyt iQue® Flow Cytometer (Essen BioScience, Inc., formerly Intellicyt Corporation, part of the Sartorius Group; Göttingen, Germany). Binding was measured as mean fluorescence intensity (MFI) of PE.

Cell-based competition assay for latozinemab antibody blocking of PGRN binding to sortilin. Recombinant human PGRN (AdipoGen Inc., San Diego, CA) was biotinylated with an EZ-Link Micro NHS-PEG4 Biotinylation Kit from ThermoScientific™/Pierce™ (Waltham, MA) according to the manufacturer’s instructions. Sortilin-expressing HEK293T cells or control cells were harvested and washed in PBS. Biotinylated human PGRN at 20 nM was added in PBS + 2% FBS with or without latozinemab or isotype control human antibodies and incubated on ice for 2 h. After washing cells thrice in PBS + 2% FBS, cells were incubated in streptavidin-allophycocyanin (APC; 1:100; eBioscience, San Diego, CA; cat. #17-4317-82, lot #4303110) on ice for 30 min. The cells were then rewashed, resuspended in PBS + 2% FBS, and analyzed using an Intellicyt iQue Flow Cytometer. PGRN binding was measured as the MFI of APC of the sortilin-expressing cell population.

Interaction between surface sortilin expression and PGRN levels in the presence of latozinemab. Human U251 cells (American Type Culture Collection, Manassas, VA) have detectable cell surface expression of human sortilin and were utilized for measuring sortilin expression. U251 cells were plated at 3000 cells per well of a 96-well plate for 24 h, followed by incubation with latozinemab or isotype control antibodies for 48 h. Cells were harvested with trypsin, washed in PBS, and labeled with Dylight^™-650 conjugated anti-sortilin antibody S2-11-650 (generated in-house). After cells were incubated with 5 μg/mL of the fluorescently conjugated sortilin antibody S2-11-650 for 1 h on ice, cells were washed thrice in PBS + 2% FBS and binding was quantified using an Intellicyt iQue Flow Cytometer as MFI of APC.

PGRN levels were quantified from the supernatants of the treated cells using an enzyme-linked immunosorbent assay (ELISA) for human PGRN, according to the manufacturer’s instructions (AdipoGen Life Sciences, Inc., San Diego, CA; cat. #AG-45A-0019YEK-KI01). Optical densities were measured at 450 nm using a BioTek Synergy HT Multi-Detection Microplate Reader (Winooski, VT). Data were analyzed using Microsoft Excel (Redmond, WA) and GraphPad Prism 9 (San Diego, CA).

In vivo assessment of an anti-sortilin antibody in a mouse model of GRN haploinsufficiency

Animals and treatment. Grn^+/− mice and wild-type (WT) littermate controls of both sexes, age 19 to 21 months at the start of experiment, were used (N = 42: 21 were male and 21 were female; there were 9–12 in each of the 4 genotype/treatment groups). Mice were on a congenic C57BL6/J background and were housed in ventilated cages in a barrier facility with 12:12 light cycles and ad libitum access to food and water. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham.

Mice underwent pretreatment social dominance testing, in which WT and Grn^+/− mice were paired to confirm the presence of the expected low dominance phenotype in Grn^+/− mice. Treatment group assignment was stratified by winning percentage; both WT treatment groups had a mean pretreatment winning percentage of 67% vs Grn^+/− mice and both Grn^+/− treatment groups had a mean pretreatment winning percentage of 33% vs WT mice. Mice were treated with weekly intraperitoneal (i.p.) injections of S15JG or isotype control at 40 mg/kg for 4 to 5 weeks (totaling 5 injections prior to testing). S15JG is a mouse cross-reactive anti-sortilin antibody that was used in the mouse studies because latozinemab is not cross-reactive to rodents. Like latozinemab, S15JG binds to the beta-propellor region of sortilin (also the binding site for progranulin [25]) but at a slightly different epitope. Antibodies were coded so that the experimenter remained blind to treatment group during both injections and behavioral testing, with blind broken only after data analysis.

After treatment with S15JG, mice were retested for social dominance using the tube test, as previously described [44, 45] and detailed below. Following the behavioral studies, mice were administered antibodies for an additional 2 weeks before euthanasia, for a total duration of 7 weeks of antibody administration. Terminal bleeds were collected and plasma PGRN and white blood cell (WBC) sortilin levels were assayed, as described below.

Tube test for social dominance. Each mouse was tested against 3 mice from the opposing group in a 3-round design. Tests were designed so that mice from each group were evenly assigned to each side of the tube to avoid an effect of tube position. In cases where one group was paired against multiple other groups, rounds were interspersed to avoid an effect of testing order. Each mouse was limited to 6 rounds of testing per day to avoid testing fatigue. The winning percentage of each mouse (number of wins/total number of matches) was calculated and analyzed by Mann–Whitney test. All analyses were conducted with GraphPad Prism 9, with 2-tailed p values and α set at 0.05.

Microdialysis sampling. To evaluate the effects of an anti-sortilin antibody in the central nervous system (CNS), a separate group of mice were implanted in the medial prefrontal cortex with guide cannulas, and microdialysis sampling was performed after a single injection of S15JG or vehicle. Specifically, guide cannulas (Amuza, Inc., San Diego, CA) were implanted in the medial prefrontal cortex of Grn^+/− and WT mice 36 to 48 h before implantation of microdialysis probes. Cannulas were implanted using a stereotaxic frame (Stoelting Co., Wood Dale, IL) at 1.9 mm anterior to bregma, 0.4 mm lateral from the midline, and 1.0 mm below the surface of the skull. Mice were injected with either S15JG or control antibody (40 mg/kg, i.p.) 24 h before probe implantations and sampling. The antibodies were coded so that the experimenters were blind to treatment group until after sampling and analysis were complete. Microdialysis probes with 2-mm membranes (AtmosLM^™, Amuza, Inc.) were implanted in the guide cannulas and perfused with artificial CSF (1.3 mM CaCl₂, 1.2 mM MgSO₄, 3 mM KCl, 0.4 mM KH₂PO₄, 25 mM NaHCO₃, 122 mM NaCl, pH 7.35) at 1 μL/min. To optimize fluid recovery and prevent protein binding to tubing, artificial CSF was supplemented with bovine serum albumin (BSA) solution (30% BSA, MilliporeSigma, Burlington, MA) at a final concentration of 4% [46, 47]. Probes were perfused using a push–pull system [48] consisting of a syringe pump (Amuza, Inc.) and a peristaltic pump (Amuza, Inc.). Based on preliminary experiments, collection of samples was delayed for 8 h after probe implantation to allow stabilization of PGRN levels in interstitial fluid (ISF). Samples were then collected in a refrigerated fraction collector (FC-90; Amuza, Inc.) at 1-h intervals for 16 h, so that samples were collected from 32 to 48 h after antibody injection. After collection was completed, ISF samples were stored at − 80 °C until analysis by ELISA.

PK/PD of latozinemab in nonhuman primates

Subjects. Twelve male cynomolgus monkeys (Macaca fascicularis), ranging from 31 to 41 months old, were used as subjects. All procedures complied with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare.

Study design. Latozinemab was administered once via intravenous (i.v.) (bolus) injection on day 1 at a dose of 0 mg/kg (placebo), 5 mg/kg, 20 mg/kg, 60 mg/kg, or 200 mg/kg. Blood samples (1 mL) were collected from the femoral vein on day 1 at pre dose, and again at approximately 0.17, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 216, 312, 480, 648, 816, and 984 h post dose for plasma and WBCs. CSF samples (0.2 mL) were collected on day 1 at pre dose, and again at approximately 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 216, 312, 480, 648, 816, and 984 h post dose. ELISA was used to measure concentrations of latozinemab and PGRN, as well as WBC expression of sortilin for PK and PD analyses.

First-in-human phase 1 study

Participants. Participants were eligible for inclusion if they met the following key criteria: males or nonpregnant females; aged 18–65 years in the HV single ascending dose (SAD) groups or 18–80 years in the aFTD-GRN group; in good physical health on the basis of no clinically significant findings; and aFTD-GRN individuals who knew their GRN mutation status. Participants were excluded from the study if they met any of the following criteria, among others: known history of reactions to antibodies or fusion proteins; positive drug or alcohol results at screening; history of alcohol or substance abuse within the past 2 years; history of seizures, major depression, schizophrenia, schizoaffective disorder, bipolar disorder, or dementia due to a condition other than FTD; history of cancer with exceptions; history of severe, clinically significant CNS trauma; or any other severe or unstable medical condition or abnormal clinical laboratory test.

Study design. Study AL001-1 (NCT03636204) was a multisite, first-in-human phase 1 study designed to evaluate the safety, tolerability, PK, and PD of latozinemab administered as a single i.v. dose in HVs or aFTD-GRN participants. Safety, tolerability, PK, and PD of latozinemab administered as multiple doses (MDs) were also assessed in a cohort of symptomatic carriers of GRN mutations causative of FTD (data not shown for MD cohort).

In the HV SAD groups, participants were randomized 6:2 to latozinemab or placebo in 5 dose groups, including 2, 6, 15, 30, and 60 mg/kg. The first HV SAD group was dosed at 2 mg/kg, with doses escalating up to 60 mg/kg in subsequent groups. The group of aFTD-GRN participants (n = 6) was dosed at 60 mg/kg latozinemab after dose escalation was complete. On day 1, all participants received a single dose of their assigned treatment. During the follow-up period, participants returned for scheduled visits on days 2, 3, 6, 8, 13, 18, 25, 30, 43, 57, 85, and 113. Safety assessments were made at all visits. Serum PK samples, PGRN plasma samples, and whole blood for WBCs were collected at predefined timepoints on days 1, 2, 3, 6, 8, 13, 18, 30, 43, 57, 85, and 113. CSF samples were collected from all participants except HVs in the 2- and 6-mg/kg dose groups on days-1 (the day prior to dosing), 2, and 18.

Study endpoints. The safety endpoints included the incidence, type, and severity of adverse events (AEs), and the incidence of dose-limiting AEs (DLAEs) or AEs that led to study discontinuation. Additional safety endpoints included changes from baseline in clinical laboratory tests, electrocardiogram (ECG) assessments, vital signs, or antidrug antibodies, and any physical or neurologic abnormalities. PK endpoints included serum and CSF concentrations of latozinemab at specified timepoints, and PK parameters, including CSF:serum partition coefficients. PD endpoints assessed changes in the levels of PGRN in plasma and CSF after dosing relative to baseline concentration, and changes in sortilin expression in WBCs after dosing relative to baseline.

Statistics. For categorical variables, frequencies and percentages were presented. Continuous variables were summarized using descriptive statistics. For PK parameters, geometric mean and 95% confidence intervals were also presented. Unless otherwise specified, baseline was defined as the last non-missing assessment, including repeated and unscheduled measurements, prior to the start of study drug administration.

The mean concentration per timepoint for each dose group was summarized for serum and CSF PK samples. All serum and CSF concentration values below the limit of quantification (BLQ) were set to 0. Partition coefficients were calculated for each timepoint as the ratio of latozinemab CSF concentration to latozinemab serum concentration.

Descriptive statistics were used to summarize the PD endpoints. PGRN plasma concentrations and sortilin WBC concentrations that were BLQ were set to half the lower limit of quantification (LLOQ). Serum latozinemab concentration vs time was used to derive PK parameters by noncompartmental methods. PK parameters were summarized for the PK population using descriptive statistics.

Study approval. The study was conducted in accordance with the general principles set forth in the international Ethical Guidelines for Biomedical Research Involving Human Subjects, International Council for Harmonisation Guideline for Good Clinical Practice, and the Declaration of Helsinki. The sponsor ensured the study complied with all local, federal, or country regulatory requirements as applicable.

The protocol and informed consent form were reviewed and approved by the institutional review board (IRB)/independent ethics committee (IEC) of each participating clinical site prior to study initiation. All serious AEs (SAEs), regardless of causality, were reported to the IRB/IEC. Participants provided informed consent prior to study enrollment.

Bioanalytical and PD procedures

For the detection of latozinemab concentrations, recombinant human sortilin was diluted in coating buffer in 96-well ELISA plates and incubated at 2–8 °C for 1 day. Diluted plasma (monkey), serum (human), or CSF (monkey or human) samples were added to the wells for 1–2 h at room temperature, followed by detection with horseradish peroxidase (HRP) conjugated goat antihuman IgG H + L monkey-adsorbed (monkey plasma or CSF), or biotinylated anti-AL001 with streptavidin-HRP A (human serum), or Pierce High Sensitivity Streptavidin-HRP (human CSF). Antibody PK parameters were calculated using Phoenix WinNonlin software.

Concentrations of PGRN were quantified in plasma (all species), CSF (monkey and human), and ISF (mouse). PGRN levels were measured by ELISA following the manufacturer’s instructions for samples collected from mice (R&D Systems; cat. #DY2557) and monkeys (AdipoGen; cat. #AG-45A-0019YEK-KI01, lot #K2701611). For detection of PGRN in human, biological samples were diluted (1:40 for plasma and 1:4 for CSF) in ELISA buffer, added to the plate, incubated for 1 h at 37 °C, and then the plate was incubated with detection antibody and HRP-labeled streptavidin solution followed by a tetramethylbenzidine (TMB) substrate solution, with washes in between each incubation. PGRN levels in ISF samples were analyzed by ELISA (AdipoGen). Prior to analysis, ISF samples were diluted 1:1 with ELISA buffer, and then loaded onto ELISA plates and analyzed according to the manufacturer’s instructions. Absorbance was read on a Biotek Synergy LX plate reader. PGRN was quantitated relative to a standard curve run on each plate. Data were analyzed with GraphPad Prism 9.

To process WBCs from mouse and monkey samples, 1 mL of ammonium-chloride-potassium (ACK) lysis buffer (Lonza) was added to 200 μL of whole blood, and then mixed and incubated on ice for 10 min. The sample was centrifuged at 500 xg for 10 min at 4 °C. The supernatant was aspirated and the pellet was resuspended in 1 mL ACK lysis buffer for 5 min on ice. The sample was recentrifuged at 500 xg for 10 min and the buffer was aspirated. The cycle was repeated until all red blood cells were lysed. For sortilin concentration, high-binding 96-well ELISA plates were coated with anti-sortilin antibody (S2-11; 1 μg/mL) in PBS at 4 °C overnight. Diluted WBC samples were added to the wells for 1 h at room temperature. Wells were then incubated with goat anti-human sortilin-biotinylated secondary antibody (0.1 μg/mL; cat. #BAF3154, lot #WTJ016011; R&D Systems) for 1 h followed by streptavidin HRP (cat. #DY998, lot #P104876; R&D Systems) for 20 min. Pierce 1-Step Ultra TMB was used for visualization and the reaction was stopped with 2N sulfuric acid. For mouse and monkey studies, optical densities were measured at 450 nm using a BioTek Synergy HT Multi-Detection Microplate Reader. Data were analyzed using Excel and GraphPad Prism 9.

The concentration of sortilin in human WBCs was assessed as follows. The S2-11 human IgG1 was diluted in coating buffer, added to the plate, and incubated overnight. The plate was washed and un-adsorbed sites were blocked with blocking buffer for 1–3 h. After washing the plate, lysed WBCs were diluted, dispensed onto the same plate, and incubated for 1 h. Then the plate was incubated with goat antihuman sortilin biotin, streptavidin-HRP A, and finally a working substrate solution, with washes in between each incubation.

Results

Latozinemab effectively binds sortilin with high affinity and blocks the interaction between PGRN and sortilin in vitro

Anti-sortilin antibodies were developed and tested for their ability to competitively block binding to PGRN in a cell-free assay. Blocking antibodies were further screened for their ability to induce sortilin degradation in a cell-based assay, and antibodies that displayed dual functionality of competitive blockade and receptor degradation were selected for antibody engineering and further studies. A lead human antibody was affinity-matured and engineered with an inert IgG1 containing L234A/L235A/P331S mutations of the heavy chain to minimize Fc receptor effector functions, and was subsequently termed latozinemab.

An HEK293T cell line stably transfected with human sortilin showed a binding curve (K_D) of 0.13 ± 0.029 nM for latozinemab (Fig. 1A), while no binding occurred on untransfected HEK293T cells (data not shown). Cell-based competition assay with biotinylated human PGRN in the presence or absence of latozinemab further demonstrated a dose-dependent blockage of biotinylated human PGRN binding (Fig. 1B).

Fig. 1.

In vitro characterization of latozinemab. A Binding curve of sortilin-expressing HEK293T cells by latozinemab. n = 4 technical replicates for latozinemab, n = 5 technical replicates for isotype control. B Percentage of dose-dependent blocking of human PGRN binding to sortilin by latozinemab. n = 3 technical replicates for latozinemab, n = 2 technical replicates for isotype control. C Dose-dependent decrease in surface sortilin expression on U251 cells. n = 3 technical replicates for latozinemab, n = 2 technical replicates for isotype control. D Extracellular PGRN is increased relative to baseline (dashed line) in the presence of latozinemab. n = 3 technical replicates for latozinemab, n = 2 technical replicates for isotype control. All data represent the mean ± SD. 2–5 technical replicates shown for each experiment, each experiment was repeated N > 3, representative data are shown. PE, phycoerythrin; PGRN, progranulin

We next determined whether latozinemab alters the endogenous levels of sortilin in human U251 cells. Latozinemab was found to reduce cell surface expression of sortilin in a dose-dependent manner, whereas cells treated with control isotype showed no appreciable change in sortilin expression (Fig. 1C). The maximal decrease in sortilin cell surface expression by latozinemab at 150 nM was 63.8%, with a half-maximal effective concentration of 0.105 ± 0.018 nM. Based on the calculated mean differences and standard deviations of the treatment groups at all doses tested, the percent decrease in sortilin cell surface levels from baseline was at least 30% more in the samples treated with latozinemab at 0.206 nM or higher doses, as compared to their respective isotype controls. To look for parallel changes in PGRN levels, PGRN was quantified from the supernatants of the treated cells. Latozinemab elicited a dose-dependent increase of PGRN of up to 2.17-fold (Fig. 1D). The mean differences and standard deviations for each dose were compared and demonstrated that extracellular PGRN levels were at least 30% higher from baseline with latozinemab at 0.023 nM or higher doses, as compared to isotype controls.

The murine cross-reactive anti-sortilin antibody S15JG increases PGRN levels in vivo and rescues a behavioral deficit in a mouse model of FTD-GRN

To determine the target engagement and efficacy of S15JG, a mouse cross-reactive antibody that partly blocks the interaction of PGRN with sortilin and strongly decreases sortilin levels, WT and Grn^+/− mice were used to model the PGRN haploinsufficiency that occurs in FTD-GRN [49]. Repeated injections of S15JG significantly reduced expression of sortilin in lysates from WBCs isolated from WT (77.6% reduction) and Grn^+/− (74% reduction) mice relative to their control-treated counterparts (Fig. 2A). The levels of PGRN in control-treated Grn^+/− mice were 50% lower than control-treated WTs, as expected (Fig. 2B) [49]. The S15JG–induced decrease in sortilin levels (Fig. 2A) was accompanied by a 3- to fivefold elevation in plasma PGRN levels in both WT and Grn^+/− mice, with PGRN being restored to above-normal levels in the S15JG–treated Grn^+/− mice (Fig. 2B). To evaluate PGRN levels in the CNS, microdialysis sampling was used to measure PGRN in the ISF following a single injection of 40-mg/kg S15JG. PGRN levels in the ISF from S15JG–treated mice of both genotypes were ~ 3 times that of their control-treated counterparts (Fig. 2C), suggesting that anti-sortilin treatment can successfully restore PGRN in the brains of Grn^+/− animals back to physiological levels.

Fig. 2.

In vivo assessment of an anti-sortilin antibody in a mouse model of GRN haploinsufficiency. A Cell lysate sortilin levels and B plasma PGRN levels from WT and Grn^+/− mice that received weekly i.p. injections of S15JG or isotype control for 4.5 weeks. C PGRN levels measured from ISF 33–48 h post injection demonstrated a significant main effect of antibody treatment (P = 0.0089) by Mann–Whitney U tests. (A-C) N = 4–6 per group. All data represent the mean ± SEM. P values are by planned post hoc Tukey’s tests and are adjusted for multiple comparisons. D Schematic of social dominance test. E–H Ratio of the number of matches won by each animal in a given matchup. Male and female pairs were tested at 19–21 months of age (n = 9–12 per group). P values are by Mann–Whitney U tests. All data represent the mean ± SEM. Anti-sort, anti-sortilin antibody S15JG; Ctl, control; ISF, interstitial fluid; PGRN, progranulin

Grn^+/− mice have been shown to display a behavioral phenotype in a social dominance assay [45]. In this assay (Fig. 2D), 2 mice are placed in a tube facing each other, and 1 of them must retreat for the mice to be able to exit the tube. The mouse that retreats is deemed the “loser.” Aged Grn^+/− mice lose the majority of these matches when paired against WT controls, but restoring neuronal PGRN in these mice is sufficient to reverse the behavioral phenotype [44, 45].

To determine if S15JG can rescue this behavioral phenotype, 21-month-old Grn^+/− mice and WT littermates were first tested to confirm the presence of the behavioral phenotype. These mice were then treated with weekly i.p. injections of 40 mg/kg S15JG or an isotype control antibody for 4.5 weeks and then retested. As expected [44, 45], control-treated Grn^+/− mice lost 70% to 80% of matches against control-treated WT littermates (Fig. 2E). However, when S15JG–treated Grn^+/− mice were tested against control-treated WT littermates, the win rate increased to approximately 40% to 50% (Fig. 2F), with a loss of a statistically significant difference between the groups. This trend suggests that restoration of PGRN back to physiological levels in the aged mice can rescue the behavioral phenotype associated with PGRN haploinsufficiency that was observed in control-treated mice. We further tested S15JG–treated Grn^+/− mice against control-treated Grn^+/− mice and found that the S15JG–treated Grn^+/− mice behaved similarly to control-treated WT mice and won 70% to 80% of the matches against control-treated Grn^+/− mice (Fig. 2G). Moreover, control-treated WT mice won similar numbers of matches against S15JG–treated WT mice (Fig. 2H), suggesting that S15JG does not lead to hyperactivity, aggression, or any other detectible adverse behavior in this test when PGRN levels are elevated above normal.

Latozinemab decreases sortilin levels in WBCs and increases PGRN levels in plasma and CSF of cynomolgus monkeys

To guide dosing parameters for a clinical trial, we next assessed the PK characteristics of varying doses of latozinemab in cynomolgus monkeys for up to 41 days after a single injection. For plasma (Fig. 3A and Additional file 1: Table S1) and CSF (Fig. 3B and Additional file 1: Table S2) latozinemab measurements, the maximum observed concentration (C_max) and area under the concentration time curve (AUC) (including AUC from time 0 to time t and AUC from time 0 to infinity) increased as the dose was increased. CSF latozinemab concentrations were approximately 0.1% of those measured in plasma, as expected for CNS penetration of monoclonal antibodies [50].

Fig. 3.

Latozinemab decreases sortilin levels in WBCs and increases PGRN levels in plasma and CSF of cynomolgus monkeys. A–B Plasma A and CSF B concentrations of latozinemab antibody as a function of time. C Sortilin concentrations measured as a function of time in WBCs. D–E Plasma D and CSF E PGRN levels measured as a function of time. Male monkeys, 24–50 months of age, were used (n = 3 per group). All data represent the mean ± SEM. Dashed lines in C-E indicate baseline. CSF, cerebrospinal fluid; PGRN, progranulin

Sortilin levels were decreased in isolated WBC lysates by all doses of latozinemab (Fig. 3C). The 60- and 200-mg/kg doses resulted in an earlier and longer-sustained decrease in sortilin levels compared with the 5- and 20-mg/kg doses (Additional file 1: Tables S3–S4). Across doses, sortilin levels were significantly decreased from baseline for 144–480 h post injection (Additional file 1: Table S3).

Maximal elevations of plasma PGRN levels across all doses of latozinemab were up to fourfold higher than baseline (Fig. 3D). The latozinemab-induced increase in plasma PGRN occurred as early as 6 h post injection for all doses but reached statistical significance at 24 h post injection (Additional file 1: Table S5). Though the C_max for plasma latozinemab measurements increased as the dose increased (Additional file 1: Table S1), the peak increase in plasma PGRN levels was similar for all doses (Fig. 3D and Additional file 1: Table S6). However, the PGRN levels remained elevated above baseline for longer durations with the higher latozinemab doses (Fig. 3D and Additional file 1: Table S6). We also quantified CSF PGRN concentrations and found that latozinemab treatment resulted in a 2- to threefold increase in CSF PGRN at the peak of the response (Fig. 3E). Although the 5-mg/kg dose did not increase CSF PGRN above baseline levels, all other doses led to a significant increase in CSF PGRN within 12–24 h post injection (Additional file 1: Table S7). The duration of the latozinemab-induced increase lasted longer with increased doses (Fig. 3E and Additional file 1: Tables S7–S8).

A single infusion of latozinemab in HVs and aFTD-GRN participants decreases WBC sortilin and increases plasma and CSF PGRN

The results of the preclinical pharmacology, PK, and PD studies prompted the start of clinical trials. AL001-1 (NCT03636204) was a first-in-human phase 1 study designed to evaluate the safety, tolerability, PK, and PD of latozinemab. In the first part of the AL001-1 study, latozinemab was administered via i.v. infusion to HVs in a SAD design, including 2-, 6-, 15-, 30-, and 60-mg/kg doses and placebo. In the second part of the study, latozinemab was administered as a single dose of 60 mg/kg to aFTD-GRN participants that had 30% to 50% of the normal levels of PGRN. For PK endpoints, serum and CSF concentrations of latozinemab were measured at specified timepoints before and after infusion. For PD assessments, changes from baseline in the levels of PGRN in plasma and CSF and in sortilin expression in WBCs were quantified.

Participants

A total of 56 participants were enrolled in the study, including 50 HVs who were randomly assigned to the SAD groups and 6 aFTD-GRN participants (Table S9). All participants received a dose of study drug or placebo.

Baseline demographics and characteristics were generally similar across treatment groups for the HVs and aFTD-GRN participants (Additional file 1: Table S10). Overall, the age of participants ranged from 19 to 71 years. More males were enrolled than females, and most participants were White.

Pharmacokinetics

Following a single infusion of latozinemab at 2–60 mg/kg in HVs, the overall shape of the mean serum concentration–time profiles for latozinemab were similar for each dose group, exhibiting mean peak exposures on day 1 (Fig. 4A). Measurable concentrations of latozinemab were seen for 30 days or longer in groups that received 30 mg/kg or greater. A similar serum concentration–time profile was seen following a single infusion in aFTD-GRN participants (Fig. 4B).

Fig. 4.

Pharmacokinetics of latozinemab in HVs and aFTD-GRN participants. A–B Mean ± SD serum concentrations of latozinemab plotted as a function of time for HVs in the SAD groups A and aFTD-GRN participants who received the 60-mg/kg dose B. For the HV SAD groups A, n = 4–13 participants/group/timepoint, and for the aFTD-GRN group B, n = 8 at all timepoints, except for days 15 (n = 7 at 4 h post dose), 85 (n = 4), and 141 (n = 3). C–D Mean ± SD CSF concentrations of latozinemab plotted as a function of time for HVs in the SAD groups C and aFTD-GRN participants D; note that CSF samples were not collected for HVs in the 2-mg/kg and 6-mg/kg dose groups. For the HV SAD groups C, n = 6 participants/group/timepoint, except for the 60-mg/kg dose group prior to dosing (n = 13) and on day 13 (n = 5). For the aFTD-GRN group D, n = 5 at all timepoints, except for day 25 (n = 1). Nominal time after dose is relative to the end of infusion. Placebo-treated subjects were excluded from the PK population. aFTD-GRN, asymptomatic carrier of GRN mutations causative of frontotemporal dementia; CSF, cerebrospinal fluid; HV, healthy volunteer

For HVs in the SAD groups, the mean CSF concentrations of latozinemab appeared to increase in a dose-dependent manner, with the highest levels observed by day 3 for the 15- and 30-mg/kg dose groups and by day 13 for the 60-mg/kg dose group (Fig. 4C). After reaching the maximum measured CSF concentrations of latozinemab, concentrations declined and approached levels near the lower limit of detection by day 42 for the 60-mg/kg dose group. CSF levels of latozinemab in aFTD-GRN participants were similar to those seen in HVs receiving the same dose (Fig. 4D). CSF:serum partition coefficients were less than 1% (Additional file 1: Table S11).

Serum PK parameters demonstrated that mean total and peak exposures of latozinemab increased with increasing dose level in the SAD groups (Additional file 1: Table S12), with approximately dose-proportional increased C_max whereas AUC values increased in a greater than proportional manner (Table S13). C_max values of latozinemab were attained ~ 1–3 h post dose for the HV SAD groups and ~ 1.5 h post dose for aFTD-GRN participants. PK parameters in aFTD-GRN participants were similar to those observed in HVs who received the same dose. In the HVs, clearance of latozinemab decreased with increasing doses of latozinemab, and the volume of distribution remained between 2.08 L and 3.15 L (Additional file 1: Table S12).

Pharmacodynamics

To assess the effect of latozinemab on sortilin levels, we quantified the concentration of sortilin and total protein in human lysed WBCs. The percentage change from baseline in WBC sortilin levels decreased following a single administration of latozinemab in both HVs and aFTD-GRN participants (Fig. 5A, B, Additional file 1: Fig. S2, and Additional file 1: Table S14). The decrease in sortilin appeared to be dose-dependent in the HV SAD groups, with a more robust and longer lasting decrease observed in participants who received the higher doses (Fig. 5A). An apparent increase in sortilin WBC levels (relative to baseline values) was observed after day 57, at which time there was no concomitant decrease in PGRN, but this was driven by 2 individuals who had abnormally low baseline sortilin values; these individuals’ post-treatment absolute sortilin levels were similar to those of other participants (Additional file 1: Fig. S1). Thus, we do not believe there was a continuous increase in sortilin WBC levels 50 + days after treatment and that the sortilin results are consistent with the PGRN results.

Fig. 5.

Latozinemab decreases sortilin in WBCs and increases PGRN levels in the plasma and CSF of HVs and aFTD-GRN participants. A–B Median percentage change from baseline in sortilin in WBCs from HVs who were administered a SAD of latozinemab A and from aFTD-GRN participants who received a single injection of 60-mg/kg latozinemab B. For the HV SAD groups A, n = 4–13 participants/group/timepoint and for the aFTD-GRN group B, n = 3–5 participants/timepont. C–D Median percentage change from baseline in PGRN levels in plasma from HVs C and from the aFTD-GRN group D. For the HV SAD groups C, n = 4–13 participants/group/timepoint and for the aFTD-GRN group D, n = 5 at all timepoints, except on days 2 (30 h post dose), 57, 85, and 113 (n = 3) E–F Median percent change from baseline in PGRN levels in CSF from HVs E and from the aFTD-GRN group F; note that CSF samples were not collected for HVs in the 2-mg/kg and 6-mg/kg dose groups. For the HV SAD groups E, n = 2–13 participants/group/timepoint and for the aFTD-GRN group F, n = 5 at baseline and day 13 and n = 1 at day 25. Nominal timepoints are relative to the end of infusion. The percent change from baseline was calculated for each individual based on their own predose value. Dashed lines indicate baseline. aFTD-GRN, asymptomatic carriers of GRN mutations causative of frontotemporal dementia; HV, healthy volunteer; PGRN, progranulin

Latozinemab administration resulted in an increase in plasma PGRN levels in the HVs (Fig. 5C), with the maximum percentage change from baseline in each of the SAD groups being significantly greater than that in the placebo-treated group (Additional file 1: Fig. S2 and Additional file 1: Table S15). Unlike the dose-dependent effect that was observed for peak serum latozinemab concentrations (Fig. 4A), the peak increase in plasma PGRN levels was comparable across doses (Fig. 5C). The increase in plasma PGRN that occurred in aFTD-GRN participants (Fig. 5D) was similar to that observed in HVs who received the same latozinemab dose. In addition, latozinemab increased CSF PGRN levels in both HVs and aFTD-GRN participants (Fig. 5E, F), with an apparent dose-dependent increase in the HVs. The relative increase from baseline in CSF PGRN levels in the 15-, 30-, and 60-mg/kg dose groups was significantly greater than in the placebo group on day 13 (Additional file 1: Fig. S2 and Additional file 1: Table S16).

Safety and tolerability

Overall, 32 of 50 HVs (64%) reported a total of 70 treatment-emergent adverse events (TEAEs), with similar rates of TEAEs reported for participants treated with latozinemab (63.2%) or placebo (66.7%; Table 1). The majority of TEAEs were mild or moderate in severity and deemed not related to the study drug. Two HVs experienced an SAE (rhabdomyolysis), neither of which was considered related to the study drug; 1 case (in which the individual received placebo) was attributed to strenuous exercise and the other case (in which the individual received 60 mg/kg latozinemab) was suspected to be due to acute alcohol intoxication and recovery. No DLAEs or TEAEs led to study discontinuation in the HVs. The most frequently reported (≥ 10%) TEAEs (Table 2) were post–lumbar puncture syndrome (n = 9; 18%) and puncture-site pain (n = 5; 10%). TEAEs generally occurred at a similar or lower incidence for participants in the latozinemab dose groups compared with the pooled placebo group, with no treatment- or dose-related trends observed for the frequency of TEAEs.

Table 1.

Summary of TEAEs (safety population)

	Double-blind, SAD HVs								Open-label
		Latozinemab dose level							aFTD-GRN 60 mg/kg (N = 6)
	Pooled placebo (n = 12)	2 mg/kg (n = 7)	6 mg/kg (n = 6)	15 mg/kg (n = 6)	30 mg/kg (n = 6)	60 mg/kg (n = 13)	Total AL001 (n = 38)	Total (N = 50)
Any TEAE, n (%) [E]	8 (66.7)	2 (28.6)	5 (83.3)	4 (66.7)	5 (83.3)	8 (61.5)	24 (63.2)	32 (64.0) [70]	4 (66.7)
Any treatment-related TEAE, n (%) [E]	1 (8.3)a	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)a	0 (0.0)	1 (2.6)	2 (4.0)	1 (16.7)b
Severity of TEAEs, n (%) [E]
Mild	0 (0.0)	0 (0.0)	2 (33.3)	1 (16.7)	0 (0.0)	3 (23.1)	6 (15.8)	6 (12.0)	4 (66.7)
Moderate	7 (58.3)	2 (28.6)	3 (50.0)	3 (50.0)	5 (83.3)	4 (30.8)	17 (44.7)	24 (48.0)	0 (0.0)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Life-threatening	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (7.7)	1 (2.6)	2 (4.0)	0 (0.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Severity of treatment-related TEAEs, n (%) [E]
Mild	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	1 (2.6)	2 (4.0)	1 (16.7)
Moderate	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Life-threatening	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Any SAE, n (%) [E]	1 (8.3)c	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (7.7)c	1 (2.6)	2 (4.0)	0 (0.0)
Any treatment-related SAE, n (%) [E]	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Any TEAE leading to discontinuation, n (%) [E]	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Any DLAE, n (%) [E]	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	NA

aFTD-GRN, asymptomatic carrier of GRN mutations causative of frontotemporal dementia; DLAE, dose-limiting adverse event; HV, healthy volunteer; SAD, single ascending dose; TEAE, treatment-emergent adverse event; SAE, serious adverse event

^a Post–lumbar puncture syndrome

^b Myalgia, lipase increased, and tachycardia

^c Rhabdomyolysis

Table 2.

TEAEs occurring in ≥ 5% participants overall

	Double-blind, single-ascending-dose healthy volunteers								Open-label
		Latozinemab dose level							aFTD-GRN 60 mg/kg (N = 6)
MedDRA preferred term n (%) [E]	Pooled placebo (n = 12)	2 mg/kg (n = 7)	6 mg/kg (n = 6)	15 mg/kg (n = 6)	30 mg/kg (n = 6)	60 mg/kg (n = 13)	Total AL001 (n = 38)	Total (N = 50)
Post–lumbar puncture syndrome	2 (16.7)	0	0	1 (16.7)	3 (50.0)	3 (23.1)	7 (18.4)	9 (18.0)	1 (16.7)
Puncture site pain	2 (16.7)	0	0	0	0	3 (23.1)	3 (7.9)	5 (10.0)	0
Headache	0	0	0	0	3 (50.0)	1 (7.7)	4 (10.5)	4 (8.0)	0
Anemia	1 (8.3)	0	0	1 (16.7)	1 (16.7)	0	2 (5.3)	3 (6.0)	0
Vomiting	0	1 (14.3)	0	0	1 (16.7)	1 (7.7)	3 (7.9)	3 (6.0)	0

aFTD-GRN, asymptomatic carrier of GRN mutations causative of frontotemporal dementia; E, number of events reported; MedDRA, medical dictionary for regulatory activities; TEAE, treatment-emergent adverse event

Four aFTD-GRN participants (66.7%) reported a total of 10 TEAEs (Table 1). All TEAEs in this group were mild in severity and the majority were not related to the study drug. One aFTD-GRN participant experienced 3 treatment-related TEAEs (myalgia, lipase increased, and tachycardia). No aFTD-GRN participants experienced an SAE or a TEAE leading to early discontinuation. No individual TEAEs were reported by more than 1 participant in the aFTD-GRN group.

Overall, no apparent differences or trends were observed among the groups in mean changes from baseline for hematology and coagulation, clinical chemistry, or urinalysis. Several participants experienced clinical laboratory abnormalities, with no notable treatment- or dose-related trends and only 1 clinical abnormality deemed possibly related to treatment (increased lipase in 1 aFTD-GRN participant). Vital sign measurements throughout the study were generally similar to those observed at baseline, and no treatment or dose-related trends in ECGs were observed. One aFTD-GRN participant experienced mild treatment-related tachycardia; no other vital sign TEAEs were considered treatment related.

Discussion

PGRN haploinsufficiency, as a result of a LOF GRN mutation, is a cause of FTD (FTD-GRN). Advances in human genetics helped to identify sortilin as a receptor for PGRN endocytosis and degradation, which is the primary determinant of PGRN levels. These advances suggest that therapeutic efforts to treat FTD-GRN could target the sortilin-PGRN axis to prevent PGRN degradation and thereby elevate its level in the brains of individuals with FTD-GRN. Here, we describe the mechanism of action and target engagement of latozinemab, a monoclonal antibody that blocks sortilin-PGRN interactions and targets the sortilin receptor for degradation in cell-based and animal studies. We further evaluated the safety profile of latozinemab and demonstrated its target engagement in a first-in-human phase 1 clinical trial with HVs and aFTD-GRN participants.

As proof of principle, we performed in vitro cell-based assays and found that latozinemab effectively binds sortilin with high affinity, blocks the interaction between PGRN and sortilin, and decreases sortilin levels on the cell surface. PGRN is a secreted lysosomal chaperone, neuronal survival factor, and immune regulatory molecule, and none of these functions have been shown to be affected by the absence of sortilin. First, genetic ablation of Sort1 leads to chronic elevation of PGRN in the brain and serum [25], but does not prevent PGRN from entering the lysosomes through multiple alternative receptors [29], or from promoting neuronal survival [51]. Second, genetic ablation of PGRN is associated with lysosomal abnormalities, inflammation, and neurodegeneration [52], whereas genetic ablation of Sort1 is not associated with such changes, and was in fact reported to protect mice from age- and injury-dependent neuronal degeneration [53]. Third, PGRN that was engineered not to bind to sortilin is functional and capable of replacing endogenous PGRN in vivo [54]. Fourth, people with genetic variations that affect SORT1 levels were not reported to display lysosomal abnormalities or neurodegeneration [24], unlike those with LOF mutations in GRN. PGRN was shown to still localize to the lysosome in the absence of sortilin through a pathway involving interactions with prosaposin, M6PR, and LRP1 [29, 55]. Although the evidence indicates that loss of sortilin does not contribute to lysosomal abnormalities, the role of PGRN on lysosomal function is crucial. Therefore, the effects of latozinemab on lysosomal biomarkers will be assessed in a phase 2 clinical trial in FTD-GRN patients (NCT03987295).

While PGRN plays an important role in lysosomal function, the full-length protein has also been shown to have important neurotrophic and immunosuppressive effects. Additionally, the protein is cleaved into 7 individual granulins and a paragranulin whose ranges of activity have not been fully elucidated [56–58]. However, there is evidence that granulins have an important function in lysosomal activity. Granulin E and multi-granulin peptides were shown to bind cathepsin D (CTSD) [59], an important lysosomal protease responsible for degradation of various substrates. Granulin E has also been shown to enhance the conversion of pro-CTSD to mature CTSD, and to increase the activity of mature CTSD [60, 61]. DeMuynk and colleagues [62] also showed that granulin E can mediate the neurotrophic effects of PGRN, independent of its binding to sortilin. Although this provides evidence that PGRN and granulin E can function independently of sortilin, the study was limited in that it did not evaluate the impact of reduced sortilin on individual granulins, a point that can be addressed in future studies. This and other work assessing the role of individual granulin peptides in FTD-GRN may lead to a better mechanistic understanding of PGRN’s role in lysosomal function and neuronal protection. Beyond its protective role for neuronal and microglial function, PGRN has been implicated in tumorigenesis, but a causal link between increased PGRN and cancer is not clear. There are diverse signaling pathways affected by PGRN, which alone may not be necessary for tumorigenesis. Blocking the interaction between PGRN and sortilin was able to prevent lung metastasis and infiltration of cancer cells [63]. Moreover, the levels of PGRN in latozinemab-treated FTD-GRN participants were similar to the levels observed in untreated, healthy individuals, which suggests that this potential risk of latozinemab in FTD-GRN patients is low.

Here, we have shown that latozinemab or the mouse cross-reactive S15JG were able to cause a robust decrease in cell surface and total sortilin levels as well as a parallel increase in PGRN levels in vivo. It is notable that we found increased PGRN levels across species in both the plasma and brain biofluid compartments post treatment (ISF via microdialysis in rodents and CSF from primates and human). Treatment of aged Grn^+/– mice for 1 month with S15JG reversed a behavioral phenotype associated with PGRN haploinsufficiency in these animals. Although this behavioral phenotype is apparent in the Grn^+/– mice , other dysfunction or pathology such as glial activation or accumulation of lipofuscin are not well defined. Arrant et al. [45] identified abnormal signaling pathways and neuronal morphology that may explain this phenotype, which was not assessed in this study. Overall, the results suggest that latozinemab can effectively target the CNS and may be able to mitigate the neuropathologic effects of decreased PGRN levels in FTD.

Clinical data were consistent with the preclinical data from rodents and nonhuman primates. Latozinemab was generally well tolerated when administered as a single i.v. dose of 2, 6, 15, 30, or 60 mg/kg to HVs or as a single i.v. dose of 60 mg/kg to aFTD-GRN participants. TEAEs were reported at similar rates in the HVs and aFTD-GRN participants, and the majority were mild or moderate in severity. No participants experienced a DLAE or TEAE leading to early study discontinuation.

Conclusions

Latozinemab is being developed for the treatment of carriers of GRN mutations causative of FTD to reduce the rate of neurodegeneration by increasing levels of PGRN in the periphery and brain. Here, latozinemab elicited a long-lasting increase in PGRN in the serum and CSF of aFTD-GRN participants, and restored PGRN levels to those of HVs. Together, these findings demonstrate that the sortilin receptor is a viable target for PGRN-based therapy, particularly in patients who have PGRN deficiency leading to FTD, and support the continued development of latozinemab. Studies are ongoing to determine if latozinemab-induced elevations in PGRN levels can slow the progression of FTD-associated neurodegeneration (NCT04374136).

Abbreviations

ACK

Ammonium-chloride-potassium

ADCC

Antibody-dependent cell-mediated cytotoxicity

AE

Adverse event

aFTD-GRN

Asymptomatic GRN mutation carriers

APC

Allophycocyanin

AUC

Area under the concentration time curve

BLQ

Below the limit of quantification

BSA

Bovine serum albumin

C9orf72

Chromosome 9 open reading frame 72

C_max

Maximum observed concentration

CNS

Central nervous system

CSF

Cerebrospinal fluid

CTSD

Cathepsin D

DLAE

Dose-limiting adverse event

ECG

Electrocardiogram

ELISA

Enzyme-linked immunosorbent assay

FACS

Fluorescence-activated cell sorting

FBS

Fetal bovine serum

FTD

Frontotemporal dementia

GRN

Progranulin gene

HRP

Horseradish peroxidase

HV

Healthy volunteer

IEC

Independent ethics committee

IgG

Immunoglobulin

i.p.

Intraperitoneal

IRB

Institutional review board

ISF

Interstitial fluid

i.v.

Intravenous

LLOQ

Lower limit of quantification

LOF

Loss of function

LRP1

Low-density lipoprotein receptor–related protein 1

M6PR

Mannose 6-phosphate receptor

MD

Multiple dose

MedDRA

Medical dictionary for regulatory activities

MFI

Mean fluorescence intensity

MRD

Minimum required dilution

PD

Pharmacodynamics

PE

Phycoerythrin

PGRN

Progranulin

PK

Pharmacokinetics

QC

Quality control

S15JG

Rodent cross-reactive anti-sortilin antibody

SAD

Single ascending dose

SAE

Serious adverse event

SORT1

Sortilin gene

TEAE

Treatment-emergent adverse event

TK

Toxicokinetic

TMB

Tetramethylbenzidine

ULOQ

Upper limit of quantification

WBC

White blood cell

WT

Wild type

Author contributions

MK, AM, RP, TS, MW, and AR conceived the experiments. MK, AM, MW, FY, HL, AA, and ER performed the experiments. MK, AM, RP, TS, AA, ER, MW, FY, and HL analyzed the data. RP, TS, AA, and ER acquired funding for the experiments. MK, RP, AA, and MW oversaw investigations. MK, RP, TS, ER, MW, and AR developed the methodology. MW was responsible for project administration. ER provided resources for the mouse studies. RP, ER, MW, and AR provided supervision. MK, ER, FY, and HL provided validation. MK and AM visualized the data. MW and AR wrote the original draft and MK, AM, RP, TS, AA, ER, MW, FY, HL, and AR revised, edited, and approved the final manuscript.

Funding

This invention was made with government support under Award Number R44AG050363 awarded by the National Institutes of Health, to A.R., T.S., and M.K. The government has certain rights in the invention. E.D.R. received support from the Bluefield Project to Cure Frontotemporal Dementia. A.A. received support from the National Institute on Aging under Award Number R21 AG068658.

Availability of data and materials

All data are available in the main text or supplementary materials.

Declarations

Ethics approval and consent to participate

All mouse studies were approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham. All procedures involving cynomolgus monkeys complied with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare. The first-in-human, phase 1 study was conducted in accordance with the general principles set forth in the international Ethical Guidelines for Biomedical Research Involving Human Subjects, International Council for Harmonisation Guideline for Good Clinical Practice, and the Declaration of Helsinki. The sponsor ensured the study complied with all local, federal, or country regulatory requirements as applicable.

Consent for publication

Not applicable.

Competing interests

A.M., H.L., and A.R. are employees of Alector LLC and may have an equity interest in Alector, Inc. M.K., T.S., R.P., M.W., and F.Y. were Alector employees at the time of manuscript conception and may have an equity interest in Alector, Inc. E.D.R. has served as a consultant to AGTC and as a DSMB member for Lilly.